| Overview |
| bsm-52009r-pe-cy7-100ul |
| ADAM17 Recombinant Antibody, PE-Cy7 Conjugated |
| WB, Flow-Cyt |
| Human, Mouse, Rat |
| Specifications |
| PE-Cy7 |
| Rabbit |
| Recombinant human ADAM17 protein, around 700-824aa. |
| 700-824/824 |
| Recombinant |
| IgG |
| Lot dependent |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 6868 |
| P78536 |
| Disintegrin and metalloproteinase domain-containing protein 17; ADAM metallopeptidase domain 17; CSVP; TACE; NISBD; CD156B; NISBD1; Snake venom-like protease; TNF-alpha convertase; TNF-alpha-converting enzyme; Tumor Necrosis Factor Alpha Converting Enzyme. |
| Cleaves the membrane-bound precursor of TNF-alpha to its mature soluble form. Responsible for the proteolytical release of soluble JAM3 from endothelial cells surface. Responsible for the proteolytic release of several other cell-surface proteins, including p75 TNF-receptor, interleukin 1 receptor type II, p55 TNF-receptor, transforming growth factor-alpha, L-selectin, growth hormone receptor, MUC1 and the amyloid precursor protein. Acts as an activator of Notch pathway by mediating cleavage of Notch, generating the membrane-associated intermediate fragment called Notch extracellular truncation (NEXT). Plays a role in the proteolytic processing of ACE2. |
| Application Dilution |
| WB |
1:300-5000 |
| Flow-Cyt |
1ug/Test |
Powered by Bioz